Journal
JACC-CARDIOVASCULAR IMAGING
Volume 10, Issue 10, Pages 1180-1193Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jcmg.2017.08.005
Keywords
amyloidosis; cardiomyopathy; cardiovascular magnetic resonance; heart failure; hypertrophic cardiomyopathy; sarcoidosis
Funding
- Philips
- Astellas
- Myocardial Solutions
- National Institutes of Health [NIH U01HL117006-01A1]
Ask authors/readers for more resources
Cardiac magnetic resonance (CMR) is a valuable tool for the evaluation of patients with, or at risk for, heart failure and has a growing impact on diagnosis, clinical management, and decision making. Through its ability to characterize the myocardium by using multiple different imaging parameters, it provides insight into the etiology of the underlying heart failure and its prognosis. CMR is widely accepted as the reference standard for quantifying chamber size and ejection fraction. Additionally, tissue characterization techniques such as late gadolinium enhancement (LGE) and other quantitative parameters such as T-1 mapping, both native and with measurement of extracellular volume fraction; T-2 mapping; and T-2* mapping have been validated against histological findings in a wide range of clinical scenarios. In particular, the pattern of LGE in the myocardium can help determine the underlying etiology of the heart failure. The presence and extent of LGE determine prognosis in many of the nonischemic cardiomyopathies. The use of CMR should increase as its utility in characterization and assessment of prognosis in cardiomyopathies is increasingly recognized.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available